Open Government Data (OGD) have the potential to support social and economic progress. However, this potential can be frustrated if these data remain unused. Although the literature suggests that OGD data sets’ metadata quality is one of the main factors affecting their use, to the best of our knowledge, no quantitative study provided evidence of this relationship. Considering about 400,000 data sets of 28 national, municipal and international OGD portals, we have programmatically analysed their usage, their metadata quality and the relationship between the two. Our analysis has highlighted three main findings. First, regardless of their size, the software platform adopted, and their administrative and territorial coverage, most OGD data sets are underutilised. Second, OGD portals pay varying attention to the quality of their data sets’ metadata. Third, we did not find clear evidence that data sets’ usage is positively correlated to better metadata publishing practices. Finally, we have considered other factors, such as data sets’ category, and some demographic characteristics of the OGD portals, and analysed their relationship with data sets’ usage, obtaining partially affirmative answers.

Cloud computing opens new perspectives for small-medium biotechnology laboratories that need to perform bioinformatics analysis in a flexible and effective way. This seems particularly true for hybrid clouds that couple the scalability offered by general-purpose public clouds with the greater control and ad hoc customizations supplied by the private ones. A hybrid cloud broker, acting as an intermediary between users and public providers, can support customers in the selection of the most suitable offers, optionally adding the provisioning of dedicated services with higher levels of quality. This paper analyses some economic and practical aspects of exploiting cloud computing in a real research scenario for the in silico drug discovery in terms of requirements, costs, and computational load based on the number of expected users. In particular, our work is aimed at supporting both the researchers and the cloud broker delivering an IaaS cloud infrastructure for biotechnology laboratories exposing different levels of nonfunctional requirements.

No abstract